Shopping Cart
Remove All
Your shopping cart is currently empty
Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a monoclonal antibody that targets the CD70 antigen. It exhibits anticancer activity by enhancing macrophage-associated phagocytosis of kidney cancer cells and inhibiting Burkitt lymphoma.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $197 | - | In Stock | |
| 5 mg | $596 | - | In Stock | |
| 10 mg | $959 | - | In Stock | |
| 25 mg | $1,420 | - | In Stock | |
| 50 mg | $1,920 | - | In Stock | |
| 100 mg | $2,590 | - | In Stock |
| Description | Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a monoclonal antibody that targets the CD70 antigen. It exhibits anticancer activity by enhancing macrophage-associated phagocytosis of kidney cancer cells and inhibiting Burkitt lymphoma. |
| In vitro | In vitro, vorsetuzumab (10 μg/mL; 2 h) augments macrophage-dependent phagocytosis of renal carcinoma cells[1]. Vorsetuzumab (10 μg/mL; 2 h) can be developed into a bispecific anti-human CD70/KWAR23 antibody. The results show that KWAR23 moderately induced macrophage phagocytosis of four renal carcinoma cell lines (RCC4, RCC10, TK10, and Caki-1)[1]. |
| In vivo | In SRG mice, vorsetuzumab (10 mg/kg; i.p.; every other day; for 12 d) inhibits the growth of Burkitt’s lymphoma cells[1]. |
| Synonyms | SGN-70 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | < 1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID |
| Molecular Weight | 146.1 kDa |
| Cas No. | 1165740-62-4 |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.